Charles River Laboratories remains a "Hold" as shares reflect both near-term headwinds and long-term disruption risks. CRL faces margin compression and weak organic growth due to muted biotech ...

Disc Medicine faces a regulatory setback as the FDA issued a CRL for bitopertin, citing insufficient clinical benefit evidence despite clear biomarker reduction. The upcoming Phase 3 APOLLO trial, ...

Charles River Laboratories International, Inc. CRL reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.39, down 10.2% year over year. The figure surpassed the Zacks Consensus Estimate ...

The Cultural, Religious, and Linguistic Rights Commission (CRL Rights Commission) has undertaken to roll out a series of campaigns aimed at tackling gender-based violence and femicide (GBVF) within ...

Charles River Laboratories (CRL) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2025. This widely-known consensus ...

A big part of Biogen's efforts to defend its spinal muscular atrophy (SMA) business has been dealt a setback by the FDA, which declined to approve a high-dose version of its flagship Spinraza product.

In a February Securities and Exchange Commission filing, Charles River Laboratories (CRL) disclosed that the US Department of Justice and the US Fish and Wildlife Service are investigating CRL’s ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Johnson & Johnson's hopes of quickly building its new cancer drug Rybrevant into a $5 billion product have been undermined by an FDA decision. The US regulator has turned down J&J's marketing ...